Jason Rhodes Sells 297,211 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 297,211 shares of Dyne Therapeutics stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $23.26, for a total transaction of $6,913,127.86. Following the completion of the transaction, the director directly owned 2,962 shares in the company, valued at $68,896.12. The trade was a 99.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN opened at $24.27 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. Dyne Therapeutics, Inc. has a one year low of $8.24 and a one year high of $25.00. The company has a 50-day simple moving average of $19.12 and a 200-day simple moving average of $18.31. The stock has a market capitalization of $4.01 billion, a price-to-earnings ratio of -7.54 and a beta of 1.06.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period last year, the firm posted ($1.05) earnings per share. On average, analysts predict that Dyne Therapeutics, Inc. will post -3.02 EPS for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

Several institutional investors have recently made changes to their positions in DYN. Hilton Head Capital Partners LLC acquired a new position in shares of Dyne Therapeutics during the 1st quarter worth $26,000. Strs Ohio acquired a new stake in shares of Dyne Therapeutics in the fourth quarter valued at about $51,000. Aster Capital Management DIFC Ltd purchased a new stake in Dyne Therapeutics during the fourth quarter worth about $84,000. Steward Partners Investment Advisory LLC boosted its holdings in Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after buying an additional 2,465 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its position in Dyne Therapeutics by 275.1% during the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after buying an additional 7,697 shares during the period. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on DYN. Evercore set a $33.00 price objective on shares of Dyne Therapeutics in a research note on Friday, May 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. TD Cowen initiated coverage on shares of Dyne Therapeutics in a report on Friday, June 26th. They issued a “buy” rating on the stock. Sanford C. Bernstein boosted their price target on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Finally, Wall Street Zen raised shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $34.17.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.